Q-omics provides the consensus-scored OR52N2 profile across patient tissues and cancer cell-line models. OR52N2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR52N2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, OR52N2 RNA expression shows 6,595 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight MESO, KICH, and KIRC as cancer lineages where OR52N2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52N2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52N2 survival associations across molecular data types. OR52N2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52N2 RNA expression–survival associations across cancer types. High OR52N2 expression shows unfavorable associations in LUSC, ACC, KICH and LIHC, but favorable associations in MESO and STAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for OR52N2 RNA expression.
This table summarizes OR52N2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for OR52N2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52N2 shows lower tumor expression in KICH, KIRC and BRCA and higher tumor expression in COAD, LIHC and STAD. The KICH box plot shows higher OR52N2 RNA expression in normal versus tumor tissue (log2 FC = −0.129, t-test p = .002).
This table shows molecular features associated with OR52N2 in patient tissues and cancer cell lines. In patient samples, OR52N2 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR52N2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and CNS.
